Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P302. A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn's disease
Authors:

L.A. Smith1, G. Naismith1, S. Barry2, K. Rankin3, J. Munro1, S. Laird1, J. Winter1, A.J. Morris1, D. Gaya1, 1Glasgow Royal Infirmary, Gastroenterology, Glasgow, United Kingdom, 2University of Glasgow, Robertson Centre for Biostatistics, Glasgow, United Kingdom, 3Glasgow Royal Infirmary, Biochemistry, Glasgow, United Kingdom

P302. Barriers to transition care for adolescents and young adults with inflammatory bowel disease: Results of a postal survey of adult and paediatric gastroenterologists
P302. The impact of induction and maintenance therapy with infliximab on mucosal healing and clinical remission in Polish pediatric patients with moderate to severe Crohn's disease
P302

Pharmacoszintigraphic investigations of a high-dose mesalazine tablet with a new coating

Authors:

G. Nicholas1, M. Nagy1, R. Hofmann*2, D. Wild1, M. Haschke3

1University of Basle, Nuclear Medizine, Basle, Switzerland, 2Tillotts Pharma, Medical Affairs, Rheinfelden, Switzerland, 3University Hospital , Clinical Pharmacology & Toxicology, Basle, Switzerland

P303.

Ulcerative colitis (UC) in the elderly – Moderate at onset but then a milder course? An IG-IBD study

Authors:

W. Fries1, A. Viola1, N. Mannetti2, M. Coppola2, I. Frankovic3, R. Monterubbianesi4, L. Cantoro4, D. Pugliese5, A. Aratri6, M. Cappello7, S. Saibeni8, M. Principi9, P. Naccarato10, G. Mocci11, F. Castiglione12, F. Callela13, A. Magarotto14, F. Caprioli15, A. Belvedere1, G. Casella16, L. Samperi17, A.C. Privitera18, G. Inserra17, S. Danese10, C. Papi19, A. Armuzzi20, A. Kohn4, R. D'Incà21, V. Annese22, F. Manguso23, 1University of Messina, Dept. of Clinical and Experimental Medicine, Messina, Italy, 2Careggi, University Hospital, Gastroenterology Unit, Florence, Italy, 3Gastroenterologia, Departimento di Medicina, Padova, Italy, 4San Camillo-Forlanini, UOC Gasteroenterologia, Roma, Italy, 5Complesso Integrato Columbus, Catholic University, IBD UNIT, Roma, Italy, 6ACO San Filippo Neri, UOC Gastroenterologia ed Epatologia, Roma, Italy, 7A.O.U. Policlinico, UOC Gastroenterologia ed Epatologia, Palermo, Italy, 8AO Fatebenefratelli e Oftalmico, UOC di Medicina Interna ed Epatologia, Milano, Italy, 9University of Bari, Gastroenterology Section (D.E.T.O.), Bari, Italy, 10Istituto Humanitas, Gastroenterologia, Milano, Italy, 11Ospedale Brodzu, UOC di Gastroenterologia, Cagliari, Italy, 12Università “Federico II” di Napoli, Gastroenterologia, Napoli, Italy, 13Ospedale San Giuseppe, UOC Gastroenterologia, Empoli (FI), Italy, 14Fondazione IRCCS Cá Grande Ospedale Policlinico di Milano, UO Gastroenterologia, Milano, Italy, 15Fondazione IRCCS Cá Grande Ospedale Policlinico di Milano, Dipartimento di Fisiopatologia medico-chirurgica e dei trapianti, Milano, Italy, 16Ospedale Desio, Dipartimento di Medicina, Desio (MB), Italy, 17University of Catania, Dip. di Scienze Mediche e Pediatriche, UO Medicina Interna, Catania, Italy, 18A.O. per l'Emergenza Cannizzaro, IBD UNIT, Catania, Italy, 19AOU Policlinico Federico II of Naples, Gastroenterology, Naples, Italy, 20Catholic University, Rome, Complesso Integrato Columbus, IBD UNIT, Roma, Italy, 21Dip. di Medicina, OC Padova, Gastroenterologia, Padova, Italy, 22Careggi, University Hospital, Gastroenterology Unit, Firenze, Italy, 23AORN A. Cardarelli, Napoli, UOC of Gastroenterology, Napoli, Italy

P303. Anticardiolipin antibodies as potential serologic markers of thrombosis risk in IBD patients; a pilot study in referral IBD center
Authors:

M. Crncevic Urek1, M. Majerovic1, S. Cukovic-Cavka1, L. Banfic2, R. Zadro3, M. Brinar1, N. Turk1, Z. Krznaric1, B. Vucelic1, 1Department of Internal medicine, Division of Gastroenterology and hepatology, 2Department of Cardiovascular Diseases, 3Department of laboratory diagnostics, Clinical unit for special and molecular hematology, University Hospital Center Zagreb, Zagreb, Croatia

P303. Certolizumab pegol in patients with inflammatory or fistulizing Crohn's disease: A long term update of compassionate use
P303. The efficacy of total enteral nutrition in inducing remission and improving nutritional status in children with moderate to severe Crohn's disease
P303

Real life effectiveness of Adalimumab for the treatment of ulcerative colitis: comparison between anti-TNF-naïve and non-naïve patients. Results from the Spanish ENEIDA Registry.

Authors:

M. Iborra*1, A. López-García2, M. Boscá3, V. García-Sánchez4, J. Hinojosa5, A. López-Sanromán6, L. Marquez7, P. Camo8, J. P. Gisbert9, M. Aceituno10, M. Calafat11, J. Guardiola12, B. Belloc13, Y. Ber14, B. Luis15, C. Rodríguez-Gutiérrez16, J. Barrio17, M. Rivero18, R. Camargo19, M. Van Domselaar20, D. Hervás21, P. Nos1

1Hospital Universitari i Politecnic La Fe and CIBERehd, Gastroenterology, Valencia, Spain, 2Hospital Clínic Barcelona and CIBERehd, Gastroenterology, Barcelona, Spain, 3Hospital Clínic Valencia, Gastroenterology, Valencia, Spain, 4Hospital Reina Sofia, Gastroenterology, Cordoba, Spain, 5Hospital de Manises, Gastroenterology, Valencia, Spain, 6Hospital Ramón y Cajal, Gastroenterología, Madrid, Spain, 7Hospital del Mar, Gastroenterology, Barcelona, Spain, 8Hospital Miguel Servet, Gastroenterology, Zaragoza, Spain, 9Hospital La Princesa, Gastroenterology, Madrid, Spain, 10Hospital Mutua de Terrassa, Gastroenterology, Barcelona, Spain, 11Hospital germans Trias i Pujol, Gastroenterology, Barcelona, Spain, 12Hospital Universitari Bellvitge, Gastroenterology, Barcelona, Spain, 13Hospital San Jorge, Gastroenterology, Huesca, Spain, 14Hospital Clínico Lozano Blesa, Gastroenterology, Zaragoza, Spain, 15Hospital de Donostia,Instituto Biodonostia, UPV/EHU and CIBERehd, Gastroenterology, Guipúzcoa, Spain, 16Complejo Hospitalario de Navarra, Gastroenterology, Pamplona, Spain, 17Hospital Rio Hortega, Gastroenterology, Valladolid, Spain, 18Hospital Marques de Valdecilla, Gastroenterology, Santader, Spain, 19Hospital Clínico Virgen de la Victoria, Gastroenterology, Málaga, Spain, 20Hospital de Torrejón, Gastroenterology, Madrid, Spain, 21Instituto de Investigación Sanitaria La Fe, Unidad Bioestadística , Valencia, Spain

P304.

Two year study of high and low dose oral vitamin D replacement therapy in adult inflammatory bowel disease

Authors:

M. Naghibi1, H.J. Hiew1, J. Saunders2, J.R.F. Cummings1, T.R. Smith1, 1University Hospital Southampton, Gastroenterology, Southampton, United Kingdom, 2Royal United Hospital NHS Trust, Gastroenterology, Bath, United Kingdom

P304. Anti-TNF based treatment regimens (triple: anti-TNF, azathioprine, antibiotic vs double: anti-TNF, azathioprine or anti-TNF, antibiotic) on complex perianal fistula healing in Crohn's disease patients: a retrospective clinical data assessment
Authors:

Y. Erzin1, I. Hatemi1, K. Ercaliskan1, D. Eyice1, B. Baca2, A.F. Celik1, 1Istanbul University Cerrahpasa Medical Faculty, Gastroenterology, Istanbul, Turkey, 2Istanbul University Cerrahpasa Medical Faculty, Surgery, Istanbul, Turkey

P304. Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: Early and long-term data from a retrospective observational study
P304. Normalization of health-related quality of life in inflammatory bowel disease patients in long remission with anti-TNFα treatment
P304

Crohn Disease localization does not contribute to the course of maintenance therapy with infliximab in children.

Authors:

M. Dadalski*, A. Wegner, J. Kierkus

The Children's Memorial Health Institute, Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, Warsaw, Poland

P305.

Tuberculosis infection in inflammatory bowel disease patients after anti-TNF therapy in a high tuberculosis prevalence rate area

Authors:

M.L. De Castro1, V. Hernández2, J.R. Pineda2, S. Pereira2, J. Martínez-Cadilla2, L. Sanromán2, I. Rodríguez-Prada2, 1Complejo Hospitalario Universitario de Vigo, Gastroenterology. IBD Unit, Vigo, Spain, 2Complejo Hospitalario Universitario de Vigo, Gastroenterology, Vigo, Spain

P305. An audit of faecal calprotectin testing in suspected inflammatory bowel disease in the under 45's
Authors:

N. Taylor1, E. Hills1, C. Sheen1, A. Al-Bahrani1, L. Grellier1, 1St Mary's Hospital IOW, Gastroenterology, Newport, United Kingdom

P305. Predictive factors of one-year mucosal healing in a cohort of ulcerative colitis patients in treatment with infliximab
P305. Therapy-related adverse events in Crohn's disease (CD) – A comparison between thiopurines, infliximab and combined therapy
P305

Infliximab serum levels do not predict remission after the induction phase in Crohn's Disease patients

Authors:

M. Chaparro*1, I. Guerra2, M. Iborra3, J.L. Cabriada4, L. Bujanda5, C. Taxonera6, V. García-Sánchez7, I. Marín-Jiménez8, M. Barreiro de-Acosta9, I. Vera10, M.D. Martín-Arranz11, B. Hernández-Breijo12, F. Mesonero13, L. Sempere14, F. Gomollón15, M. Mora16, M. Ramas1, A. Algaba2, B. Beltrán3, I. Moraleja4, A. Arbelaiz17, J.L. Mendoza6, E. Iglesias-Flores7, L. Menchén8, R. Ferreiro9, C. Suárez Ferrer10, S. Gómez Senent11, L. Guijarro12, P.M. Linares1, J.P. Gisbert1

1Hospital Universitario de La Princesa, IIS-IP and CIBERehd, Gastroenterology Unit, Madrid, Spain, 2Hospital Universitario de Fuenlabrada, Gastroenterology Unit, Madrid, Spain, 3Hospital Universitario La Fe and CIBERehd, Gastroenterology Unit, Valencia, Spain, 4Hospital Galdakao, Gastroenterology Unit, Vizcaya, Spain, 5Hospital de Donostia, Instituto Biodonostia, UPV/EHU and CIBEREHD, Gastroenterology Unit, Guipuzcoa, Spain, 6Hospital Clínico Universitario San Carlos and IdISSC, Gastroenterology Unit, Madrid, Spain, 7Hospital Universitario Reina Sofía, Gastroenterology Unit, Córdoba, Spain, 8Hospital General Universitario Gregorio Marañón, Gastroenterology Unit, Madrid, Spain, 9Complejo Hospitalario Universitario de Santiago, Gastroenterology Unit, Santiago de Compostela, Spain, 10Hospital Universitario Puerta de Hierro , Gastroenterology Unit, Madrid, Spain, 11Hospital Universitario La Paz , Gastroenterology Unit, Madrid, Spain, 12Universidad de Alcalá and CIBERehd, Systems Biology, Alcalá de Henares, Spain, 13Hospital Universitario Ramón y Cajal, Gastroenterology Unit, Madrid, Spain, 14Hospital General Universitario de Alicante, Gastroenterology Unit, Alicante, Spain, 15Hospital Clínico Universitario Lozano Blesa and CIBERehd, Gastroenterology Unit, Zaragoza, Spain, 16Hospital de Manises, Gastroenterology Unit, Valencia, Spain, 17Hospital de Donostia, Instituto Biodonostia, UPV/EHU and CIBEREHD, Gastroenterology Unit, San Sebastián, Spain

P306.

Tryptophan deficiency in Crohn's disease

Authors:

S. Nikolaus1, N. Al-Massad1, J. Bethge1, G. Wätzig2, P. Rosenstiel3, R. Junker4, F. Thieme4, S. Schreiber1, 1University Hospital Schleswig-Holstein, Campus Kiel, 1st Med. Department, Kiel, Germany, 2Conaris Research Institute, Research, Kiel, Germany, 3Institute of Clinical Molecular Biology, Research, Kiel, Germany, 4University Hospital Schleswig-Holstein, Campus Kiel, Institut für Klinische Chemie, Kiel, Germany